Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

B&L PureVision

This article was originally published in The Gray Sheet

Executive Summary

Washington D.C. federal appeals court declines to stay injunction against sales of the Bausch & Lomb extended-wear contact lens after a lower court's patent infringement ruling. The appeals process could take six-to-18 months, B&L says. As a result, the firm will move its PureVision manufacturing facilities to Ireland to ensure a continued supply to customers in Europe and Asia. A Delaware federal court found on June 26 that the device infringes a patent owned by CIBA Vision unit Wesley Jessen, blocking U.S. sales and production (11"The Gray Sheet" July 29, 2002, p. 17). B&L expects the decision will cost it $10 mil. in sales and $0.12-0.15 in earnings per share for the second half of 2002...
Advertisement

Related Content

Ciba Settles Cooper Lens Dispute; New CEO Brings Global Marketing Fluency
B&L Awaits PureVision Court Decision; Restructuring Plan Cuts 450 Jobs
B&L Awaits PureVision Court Decision; Restructuring Plan Cuts 450 Jobs
Advertisement
UsernamePublicRestriction

Register

MT016955

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel